Efficacy and Safety of Immunosuppressive Therapy for PBC–AIH Overlap Syndrome Accompanied by Decompensated Cirrhosis: A Real-World Study

Table 3

Histological features of the decompensated PBC-AIH patients.

Variables	UDCA-only group (N=14)	UDCA+IS group (N=14)	P value
Number of portal areas	10	9	0.541
Severe interface hepatitis	0/14	2/14	0.481
Moderate interface hepatitis	14/14	12/14	0.481
Hepatocyte rosette formation	8/14	10/14	0.695
Lymphoplasmacytic infiltrate	13/14	13/14	>0.999
Emperipolesis	0/14	0/14	-
Bile duct damage	13/14	10/14	0.326
Ductopenia	9/14	6/14	0.449
Bile duct proliferation	11/14	9/14	0.678
Cholestasis	7/14	6/14	>0.999
G0/1/2/3/4 (N)	0/0/2/12/0	0/1/2/7/4	0.374
S0/1/2/3/4 (N)	0/3/4/5/2	0/0/3/8/3	0.117

Note. UDCA, ursodeoxycholic acid; IS, immunosuppressants.